ADORA2A and breast carcinoma: In conclusion, our study demonstrated that 20.8% of diverse cancers expressed high levels of ADORA2A transcripts, with the greatest proportions of high expressors in neuroendocrine and breast cancers and in sarcomas, and with colorectal and ovarian cancers having the lowest proportion of high expressors.